Onchocerciasis in Ecuador: Evolution of chorioretinopathy after amocarzine treatment

British Journal of Ophthalmology

Volumn 80, Issue 4, 1996, Pages 337-342

  Cooper, P J ^a   Proano R ^a   Beltran, C ^a   Anselmi, M ^a   Guderian, R H ^a  

^a HOSPITAL VOZANDES   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

AMOCARZINE; ANTINEMATODAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHORIORETINOPATHY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; ECUADOR; FOLLOW UP; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; NEWBORN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PIGMENT EPITHELIUM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD;

EID: 0029911578     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.80.4.337     Document Type: Article

References (42)

1. World Health Organisation Expert Committee on Onchocerciasis, third report. Technical Report Series 752. Geneva: WHO, 1987.
2. Thylefors B. Ocular onchocerciasis. Bull WHO 1978; 56: 63-78.
3. Semba RD, Murphy RP, Newland HS, Awadzi K, Greene BM, Taylor HR. Longitudinal study of lesions of the posterior segment in onchocerciasis. Ophthalmology 1990; 97: 1334-41.
4. Newland HS, White AT, Greene BM, Murphy RP, Taylor HR. Ocular manifestations of onchocerciasis in a rain forest area of West Africa. Br J Ophthalmol 1991; 75: 163-9.
5. Abiose A, Murdoch I, Babalola O, Cousens S, Liman I, Onyema J, et al. Distribution and aetiology of blindness and visual impairment in mesoendemic onchocercal communities, Kaduna State, Nigeria. Br J Ophthalmol 1994; 78:8-13.
6. Striebel HP, Gallay JJ, Gelzer J, Jenny EF, Rao VR, Reddy AB, et al. Three new chemotherapeutic agents with potent antifilarial activity. Trop Med Parasitol 1986; 37: 91.
7. Soula G, Pichard E, Doumbo O, Soula E, Poltera A, Striebel HP. Activity of thiocarbamazine in patients dually infected with Schistosoma and Onchocerca volvulus. Lancet 1989; 1: 726.
8. Guderian RH, Anselmi M, Proaño R, Naranjo A, Poltera AA, Moran M, et al. Onchocercicidal effect of three drug regimens of amocarzine in 148 patients of two races and both sexes from Esmeraldas, Ecuador. Trop Med Parasitol 1991; 52: 263-85.
9. Zea-Flores G, Beltranena F, Poltera AA, Lopez M, Moran M, Zea-Flores CE, et al. Amocarzine investigated as oral onchocercicidal drug in 272 adult male patients from Guatemala. Results from three dose regimens spread over three days. Trop Med Parasitol 1991; 42: 240-62.
10. Anderson J, Fuglsang H. Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin. Br J Ophthalmol 1978; 62: 450-7.
11. Bird AC, El Sheikh H, Anderson J, Fuglsang H. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol 1980; 64: 191-200.
12. Budden FH. The natural history of ocular onchocerciasis over a period of 14-15 years and the effect on this of a single course of suramin therapy. Trans R Soc Trop Med Hyg 1976; 70: 484-91.
13. Anderson J, Fuglsang H, Marshall TF de C. Studies on onchocerciasis in the United Cameroon Republic. A four year follow-up of 6 rain-forest and 6 savanna villages. Trans R Soc Trop Med Hyg 1976; 70: 362-73.
14. Rolland A, Thylefors B, Pairault C. Evolution sur 9 ans de l'onchocercose oculaire dans une communaute villageoise d'Afrique occidentale. Bull Organ Mond Sante 1978; 56: 805-10.
15. Anderson J, Fuglsang H, Marshall TF de C. Effects of diethylcarbamazine on ocular onchocerciasis. Tropenmed Parasitol 1976; 27: 263-78.
16. Anderson J, Fuglsang H, Marshall TF de C. Effects of suramin on ocular onchocerciasis. Tropenmed Parasitol 1976; 27: 279-96.
17. Dadzie KY, Remme J, Rolland A, Thylefors B. The effect of 7-8 years of vector control on the evolution of ocular onchocerciasis in West African savanna. Trop Med Parasitol 1986; 37: 263-70.
18. Van der Lelij A, Rothova A, Stilma JS, Vetter JCM, Hoekzema R, Kijlstra A. Humoral and cell-mediated immune response against human retinal antigens in relation to ocular onchocerciasis. Acta Leidensia 1990; 51: 271-83.
19. Braun G, McKechnie NM, Connor V, Gilbert CE, Engelbrecht F, Whitworth JA, et al. Immunological cross-reactivity between a cloned antigen of Onchocerca volvulus and a component of the retinal pigment epithelium J Exp Med 1991; 174: 169-77.
20. McKechnie NM, Braun G, Connor V, Klager S, Taylor DW, Alexander RA, et al. Immunologic cross-reactivity in the pathogenesis of ocular onchocerciasis. Invest Ophthalmol Vis Sci 1993; 34: 2888-902.
21. Guderian RH, Leon LA, Leon R, Corral F, Vasconez C, Johnston TS. Report on a focus of onchocerciasis of Esmeraldas province of Ecuador. Am J Trop Med Hyg 1982; 31: 270-4.
22. Cooper PJ, Proaño R, Beltran C, Anselmi M, Guderian RH. Onchocerciasis in Ecuador: ocular findings in Onchocerca volvulus infected individuals. Br J Ophthalmol 1995; 79: 157-62.
23. McCullagh P, Nelder JA. Generalised linear models. Monographs on statistics and applied probability No 37. London: Chapman and Hall, 1992: 118-9.
24. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991: 431-3.
25. Rothova A, Van der Lelij A, Stilma JS, Klaassen-Broekema N, Wilson WR, Barbe RF. Ocular involvement in patients with onchocerciasis after repeated treatment with ivermectin. Am J Ophthalmol 1990; 110: 6-16.
26. Dadzie KY, Remme J, Alley ES, de Sole G. Changes in ocular onchocereiasis four and twelve months after community-based treatment with ivermectin in a holoendemic onchocereiasis focus. Trans R Soc Trop Med Hyg 1990; 84: 103-8.
27. World Health Organisation. The effect of repeated ivermectin treatment on ocular onchocereiasis; report of an informal consultation. TDR/TDE/ONCHO/93.3, 1993.
28. World Health Organisation. The pathogenesis and treatment of ocular onchocereiasis. TDR/FIL/SWG(8)/82.3, 1982.
29. Taylor HR, Murphy RP, Newland HS, White AT, D'Anna SA, Keyvan-Larijani E, et al. Treatment of onchocereiasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol 1986; 104: 863-70.
30. Bird AC, Anderson J, Fuglsang H. Morphology of posterior segment lesions of the eye in patients with onchocereiasis. Br J Ophthalmol 1976; 60: 2-20.
31. Friedman CT, Knox DL. Variations in recurrent active toxoplasmosis retinochoroiditis. Arch Ophthalmol 1969; 81: 481-93.
32. Doft BH, Gass JD. Outer retinal layer toxoplasmosis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 78-82.
33. Anderson J, Fuglsang H, Marshall TF de C, Radolowicz A, Vaughan JP. Studies on onchocereiasis in the United Cameroon Republic. IV. A four-year follow-up of six rainforest and six savanna villages. The incidence of ocular lesions. Trans R Soc Trop Med Hyg 1978; 72: 513-5.
34. Guderian RH, Beck BJ, Proano SR, Mackenzie CD. Onchocereiasis in Ecuador, 1980-1986: epidemiological evaluation of the disease in the Esmeraldas Province. Eur J Epidemiol 1989; 5: 294-302.
35. Guderian RH, Beck BJ, Proano SR. Onchocerciasis in Ecuador: infection in children in the Santiago Basin focus, Province of Esmeraldas. Trans R Soc Trop Med Hyg 1990; 84: 109-12.
36. Guderian RH, Shelley AJ. Onchocerciasis in Ecuador: the situation in 1989. Mem Inst Oswaldo Cruz 1992; 87: 405-15.
37. Rodger FC. The pathogenesis and pathology of ocular onchocerciasis. IV. The pathology. Am J Ophthalmol 1960; 49: 560-94.
38. Fuglsang H, Anderson J, Marshall TF de C. The head nodule and ocular onchocerciasis in Africa. Tropenmed Parasitol 1976; 27: 355-64.
39. Fuglsang H, Anderson J. Further observations on the relationship between ocular onchocerciasis and the head nodule, and on the possible benefit of nodulectomy. Br J Ophthalmol 1978; 62: 445-9.
40. Dadzie KY, Remme J, De Sole G. Epidemiological impact of vector control II. Changes in ocular onchocerciasis. Acta Leidensa 1990; 59: 127-39.
41. Vingtain P, Thillaye B, Karpouzas I, Faure JP. Longitudinal study of microfilarial infestation and humoral immune response to filarial and retinal antigens in onchocerciasis patients treated with ivermectin. Abstract. Ophthalmic Res 1988; 20: 95.
42. Cooper PJ, Guderian RH, Proaño R, Taylor DW. Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy. Invest Ophthalmol Vis Sci (in press).